Danaher Corp
DHRQ2 2023(DHR Q1 FY2023)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$676.5M
AI Revenue (Q)
$59.5M
Total Revenue (Q)
$5.9B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q1 FY2023 (three-month period ended March 31, 2023). Total sales $7,167M (including E&AS). Segments: Biotechnology $1,864M, Life Sciences $1,709M, Diagnostics $2,376M, Environmental & Applied Solutions $1,218M. No AI revenue disclosure. No mention of AI or machine learning in the filing. DHR continues to be a hardware/consumables business with some embedded software in instruments. Conservative 1% estimate. Math: ~$72M estimated / $7,167M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $7,167 [three-month period ended March 31, 2023]
10-Q Q1 FY2023, Consolidated Condensed Statements of Earnings
Biotechnology $1,864; Life Sciences $1,709; Diagnostics $2,376; Environmental & Applied Solutions $1,218 [three-month period ended March 31, 2023]
10-Q Q1 FY2023, Note 5 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instrumentsEnvironmental & Applied Solutions
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix